Clarus Therapeutics Holdings Inc. (CRXT)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $2 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-32 Mln

Clarus Therapeutics Holdings Inc. (CRXT) Share Price

$0.02

As on 08-Nov-2022 09:30 EST

up-down-arrow $-0.01-19.54%

  • Prev Close info

    $0.03

  • Day's Openinfo

    $0.03

  • Today's Highinfo

    $0.03

  • Today's Lowinfo

    $0.02

  • Today's Volumeinfo

    84,737

  • 52 Week rangeinfo

    $-- - --

Please wait...

Clarus Therapeutics Holdings Inc. (CRXT) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Clarus Therapeutics Holdings (CRXT)
-99.14 -46.84 -93.07 -99.59 -- -- --
S&P BSE Healthcare*
12.84 9.05 20.34 60.77 18.61 21.62 13.14
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 08-Nov-2022  |  *As on 21-Feb-2024  |  #As on 26-Oct-2023
The underlying data is unavailable.

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Clarus Therapeutics Holdings Inc. (CRXT) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Clarus Therapeutics Holdings Inc. (CRXT)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Clarus Therapeutics Holdings Inc. (CRXT)

        Founder, Pres, CEO & Director

        Dr. Robert E. Dudley Ph.D.

        Chief Financial Officer

        Mr. Richard Dale Peterson

        Headquarters

        Northbrook, IL

        FAQs for Clarus Therapeutics Holdings Inc. (CRXT)

        The total asset value of Clarus Therapeutics Holdings Inc. (CRXT) stood at $ 111 Mln as on 30-Jun-22

        The share price of Clarus Therapeutics Holdings Inc. (CRXT) is $0.02 (NASDAQ) as of 08-Nov-2022 09:30 EST. Clarus Therapeutics Holdings Inc. (CRXT) has given a return of -99.59% in the last 1 years.

        Clarus Therapeutics Holdings Inc. (CRXT) has a market capitalisation of $ 2 Mln as on 08-Nov-2022. As per Value Research classification, it is a Small Cap company.

        Since, TTM earnings of Clarus Therapeutics Holdings Inc. (CRXT) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Clarus Therapeutics Holdings Inc. (CRXT) and enter the required number of quantities and click on buy to purchase the shares of Clarus Therapeutics Holdings Inc. (CRXT).

        Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

        The CEO & director of Dr. Robert E. Dudley Ph.D.. is Clarus Therapeutics Holdings Inc. (CRXT), and CFO & Sr. VP is Mr. Richard Dale Peterson.

        The promoters of Clarus Therapeutics Holdings Inc. (CRXT) have pledged 0% of the total equity as on Sep-22.

        Clarus Therapeutics Holdings Inc. (CRXT) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Clarus Therapeutics Holdings Inc. (CRXT) was $-32 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2.47 Mln
        • Revenue (TTM)revenue-information $19.24 Mln
        • Earnings (TTM) earning-information $-32.22 Mln
        • Cash date-information $19.17 Mln
        • Total Debt info $40.51 Mln
        • Insider's Holding 2.59%
        • Liquidity liquidity
        • 52 Week range week-range $-- - --
        • Shares outstanding share-outstanding 52,020,700
        • 10 Years Aggregate:

          CFO: $-142.49 Mln

          EBITDA: $-4.94 Mln

          Net Profit: $-36.27 Mln

        About The Company

        • IPO Date 09-Sep-2021
        • Founder, Pres, CEO & Director Dr. Robert E. Dudley Ph.D.
        • Chief Financial Officer Mr. Richard Dale Peterson
        • Listing key-listing NASDAQ: CRXT
        • Country United States
        • Headquarters headquarters Northbrook, IL
        • Website website https://clarustherapeutics.com
        • Business

          Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate...  for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.  Read more

        share-fund-plan-icon